Comparison
While Exenatide is used for type 2 diabetes treatment to improve glycemic control and modestly reduce body weight through GLP-1–like insulinotropic and glucagonostatic effects6768, Liraglutide is approved for type 2 diabetes and weight management, improving glycemic control and inducing weight loss through GLP-1–mediated insulinotropic, glucagonostatic, and appetite-suppressing actions6880.
While Exenatide works as a 39-amino-acid exendin-4 peptide originally isolated from Gila monster venom that acts as a long-acting GLP-1 receptor agonist resistant to DPP-4 degradation67, Liraglutide is a human GLP-1 analog with a single amino-acid substitution (Lys34→Arg) and a C16 palmitoyl fatty acid attached to Lys26 via a glutamate linker, producing a long-acting GLP-1 receptor agonist6880.
Exenatide is 39 amino acids long, whereas Liraglutide is shorter as it has a length of 31 amino acids. Exenatide is made up of a sequence of sequence data not available in the current dataset. Liraglutide is made up of a sequence of sequence data not available in the current dataset.
Exenatide
Not assigned in the current dataset.
Liraglutide
GCG